Integral Biosystems, LLC Announces Trademark Protection for its Intellectual Property Subsidiary

Published: Sep 10, 2010

PRLog (Press Release) – Sep 08, 2010 – Integral BioSystems Announces Trademark Protection for its Intellectual Property Subsidiary

By Integral BioSystems, LLC Dated: September 8, 2010

Boston area CRO Integral BioSystems, LLC announces that the name of its Intellectual Property subsidiary, Patents Etcetera, has been granted trademark protection by the United States Patent and Trademark Office.

“With the Patents Etcetera brand now trademark protected, and with like protection for Integral BioSystems, LLC now pending in the United States Patent and Trademark Office, we anticipate a fruitful relationship for years to come under each firm’s respective banner.”

-Dave Karasic, J.D. V.P. Business Development/Legal/I.P. Integral BioSystems, LLC 781-879-4677

About Patents Etcetera

Located near Boston, Massachusetts, Patents Etcetera is an intellectual property firm founded in 2006 to provide expert patent filing services to individual inventors, seed companies, pre- start-ups and small businesses. Since its inception, Patents Etcetera has filed patent applications in the areas of drug delivery, drug dosage forms in ophthalmics, dentistry and vaccines, nanotechnology products and mechanical device designs. By teaming up with Integral BioSystems, LLC in 2008, Patents Etcetera has been able to expand its reach into the Boston area’s growing biotechnology-based industry.

About Integral BioSystems, LLC

Integral BioSystems, LLC, founded in 2008, has adopted a translational medicinal approach to drug development, customizing delivery systems to accomplish the biologically effective objectives of the therapy. Drug delivery systems are customized to achieve sustained release or targeted, tissue-focused delivery, or fast-release/instant delivery, depending upon the desired product attributes. The company has a network of manufacturers/analytical houses for pharmaceutics that can fast-track the manufacture and release of the sterile dosage form for first-in-man trials.

Back to news